World Journal of Cardiovascular Diseases

Volume 3, Issue 1 (January 2013)

ISSN Print: 2164-5329   ISSN Online: 2164-5337

Google-based Impact Factor: 0.46  Citations  h5-index & Ranking

Atrial fibrillation ablation in patients with heart failure review

HTML  XML Download Download as PDF (Size: 238KB)  PP. 49-57  
DOI: 10.4236/wjcd.2013.31011    4,260 Downloads   6,964 Views  

ABSTRACT

Atrial fibrillation and heart failure often coexist in patients with advanced heart failure symptoms. The result, in addition to a significant impact on quality of life, is an increase in the risk of a adverse clinical outcomes including stroke, hospitalization and overall mortality. Pharmacological therapy for atrial fibrillation in the heart failure population remains limited due to sub-optimal drug efficacy and a likely increased mortality due to pro-arrhythmia. Atrial fibrillation ablation, since it allows for therapy without the need for toxic medication, has the potential to become mainstream treatment in patients with drug refractory, symptomatic atrial fibrillation and heart failure. Randomized studies and observational data suggest that atrial fibrillation ablation provides superior rhythm control to anti-arrhythmic drugs. Atrial fibrilla- tion ablation is relatively safe and may result in improvement of left ventricular function and quality of life. Ongoing studies are attempting to assess a number of outcome measures to help define its role in the heart failure patient population. This review focuses on atrial fibrillation ablation in patients with congestive heart failure, and summarizes the results of available literature.

Share and Cite:

Amin, M. , Sterns, L. , Leather, R. and Tang, A. (2013) Atrial fibrillation ablation in patients with heart failure review. World Journal of Cardiovascular Diseases, 3, 49-57. doi: 10.4236/wjcd.2013.31011.

Cited by

No relevant information.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.